% | $
Quotes you view appear here for quick access.
Options Center

Options market sees Celladon heart drug as all-or-nothing bet

Reuters By Saqib Iqbal Ahmed NEW YORK (Reuters) - Celladon Corp's shares could either double in value or collapse over the next four weeks after the drug developer announces results from a heart failure gene therapy trial, options data shows. Later this month, Celladon is expected to report results from a mid-stage study of Mydicar, its experimental gene therapy for advanced heart failure, a con…